![]() | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H22ClFN6O2 |
Molar mass | 432.88 g·mol−1 |
3D model (JSmol) | |
| |
|
Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies. It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.[1][2]
References
- ^ Gerds AT, Bartalucci N, Assad A, Yacoub A (August 2022). "Targeting the PI3K pathway in myeloproliferative neoplasms". Expert Review of Anticancer Therapy. 22 (8): 835–843. doi:10.1080/14737140.2022.2093192. hdl:2158/1351132. PMID 35763287.
- ^ "Parsaclisib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.